Apellis Pharmaceuticals (APLS)

:APLS

US Market

APLS

Apellis Pharmaceuticals

RESEARCH TOOLSreports

Apellis Pharmaceuticals (APLS) Price & Analysis

― Followers

APLS Stock Chart & Stats

$41.03

$0.00(0.00%)

May 19, 2026

―

--

Day’s Range― - ―

52-Week Range― - ―

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

N/A

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

BetaN/A

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Apellis Pharmaceuticals News

Biogen completes acquisition of Apellis Pharmaceuticals

Biogen completes acquisition of Apellis Pharmaceuticals

Biogen (BIIB) announced the successful completion of the acquisition of Apellis Pharmaceuticals (APLS). Apellis is now a wholly...

3M ago

Apellis Completes Biogen Merger and Goes Private

Apellis Completes Biogen Merger and Goes Private

Apellis Pharmaceuticals ( ($APLS) ) has issued an update. Apellis Pharmaceuticals has entered into a contingent value rights...

3M ago

Remitly Global to replace Apellis in S&P 600 at open on 5/14

Remitly Global to replace Apellis in S&P 600 at open on 5/14

Remitly Global (RELY) will replace Apellis Pharmaceuticals (APLS). S&P 500 constituent Biogen (BIIB) is acquiring Apellis Pharmaceuticals in...

3M ago

Apellis Updates Executive Separation Plan Amid Biogen Merger

Apellis Updates Executive Separation Plan Amid Biogen Merger

An announcement from Apellis Pharmaceuticals ( ($APLS) ) is now available. On April 28, 2026, Apellis Pharmaceuticals’ compensation...

3M ago

Biogen price target raised to $260 from $246 at Guggenheim

Biogen price target raised to $260 from $246 at Guggenheim

Guggenheim raised the firm’s price target on Biogen (BIIB) to $260 from $246 and keeps a Buy rating...

3M ago

Biogen reports Q1 adjusted EPS $3.57, consensus $2.95

Biogen reports Q1 adjusted EPS $3.57, consensus $2.95

Reports Q1 revenue $2.48B, consensus $2.25B. President and Chief Executive Officer Christopher Viehbacher said: “We significantly advanced our...

3M ago

Wells Fargo downgrades Apellis to Equal Weight following Biogen’s acquisition

Wells Fargo downgrades Apellis to Equal Weight following Biogen’s acquisition

As previously reported, Wells Fargo analyst Derek Archila downgraded Apellis (APLS) to Equal Weight from Overweight with a...

3M ago

Apellis downgraded to Equal Weight from Overweight at Wells Fargo

Apellis downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded Apellis (APLS) to Equal Weight from Overweight with a price target of $41, up from...

3M ago

Tesla upgraded, AppLovin initiated: Wall Street’s top analyst calls

Tesla upgraded, AppLovin initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

4M ago

Apellis price target raised to $41 from $21 at RBC Capital

Apellis price target raised to $41 from $21 at RBC Capital

RBC Capital analyst Lisa Walter raised the firm’s price target on Apellis (APLS) to $41 from $21 and...

4M ago

3 Best Trending Stocks, According to Analysts – 4/2/2026

3 Best Trending Stocks, According to Analysts – 4/2/2026

TipRanks’ Trending Stocks tool allows users to filter activity over the past 30 days, seven days, or even...

4M ago

Apellis price target raised to $41 from $20 at Mizuho

Apellis price target raised to $41 from $20 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Apellis (APLS) to $41 from $20 and keeps...

4M ago

Apellis downgraded to Neutral from Buy at Roth Capital

Apellis downgraded to Neutral from Buy at Roth Capital

Roth Capital analyst Adam Walsh downgraded Apellis (APLS) to Neutral from Buy with a price target of $41,...

4M ago

Apellis: Hold Rating as Biogen Takeout Caps Upside and CVR Payouts Look Unlikely Under Conservative Syfovre Outlook

Apellis: Hold Rating as Biogen Takeout Caps Upside and CVR Payouts Look Unlikely Under Conservative Syfovre Outlook

Apellis Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ryan Deschner from...

4M ago

APLS FAQ

What was Apellis Pharmaceuticals’s price range in the past 12 months?

Currently, no data Available

What is Apellis Pharmaceuticals’s market cap?

Currently, no data Available

When is Apellis Pharmaceuticals’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Apellis Pharmaceuticals’s earnings last quarter?

Currently, no data Available

Is Apellis Pharmaceuticals overvalued?

According to Wall Street analysts Apellis Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Apellis Pharmaceuticals pay dividends?

Apellis Pharmaceuticals does not currently pay dividends.

What is Apellis Pharmaceuticals’s EPS estimate?

Apellis Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Apellis Pharmaceuticals have?

Currently, no data Available

What happened to Apellis Pharmaceuticals’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Apellis Pharmaceuticals?

Currently, no hedge funds are holding shares in APLS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Popular Stocks